NCT06732154

A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HRS-5632 Following a Single Subcutaneous Injection in Healthy Subjects

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	HRS-5632	HRS-5632 Injection
DRUG	Placebo	Sodium chloride injection

Timeline

• Start date: 2024-12-02
• Primary completion: 2026-03-02
• Completion: 2026-03-02
• First posted: 2024-12-13
• Last updated: 2026-04-03

Locations

1 site across 1 country: China